161 related articles for article (PubMed ID: 35983301)
1. Carbapenems versus Cephalosporin or Piperacillin-Tazobactam as Perioperative Antibiotic Prophylaxis in Liver Transplant Recipients with Model for End-Stage Liver Disease Scores of ≥30: A Retrospective Study in a Chinese Population.
Zhang W; Chen Y; Zhang Y; Wang R; Wang W; Bai X; Liang T
Infect Drug Resist; 2022; 15():4487-4494. PubMed ID: 35983301
[TBL] [Abstract][Full Text] [Related]
2. Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study.
Rando E; Salvati F; Sangiorgi F; Catania F; Leone E; Oliva A; Di Gennaro F; Fiori B; Cancelli F; Figliomeni S; Bobbio F; Sacco F; Bavaro DF; Diella L; Belati A; Saracino A; Mastroianni CM; Fantoni M; Murri R
J Antimicrob Chemother; 2024 Feb; 79(2):453-461. PubMed ID: 38169441
[TBL] [Abstract][Full Text] [Related]
3. Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study.
Al Muqati H; Al Turaiki A; Al Dhahri F; Al Enazi H; Althemery A
J Infect Public Health; 2021 Mar; 14(3):306-310. PubMed ID: 33618274
[TBL] [Abstract][Full Text] [Related]
4. Drug Resistance and Risk Factors for Acquisition of Gram-Negative Bacteria and Carbapenem-Resistant Organisms Among Liver Transplant Recipients.
Wu X; Long G; Peng W; Wan Q
Infect Dis Ther; 2022 Aug; 11(4):1461-1477. PubMed ID: 35551638
[TBL] [Abstract][Full Text] [Related]
5. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and outcomes of early infection in liver transplant recipients with acute-on-chronic liver failure.
Qian YB; Chen F; Hang HL; Shen C; Han LZ; Deng YX; Xia L; Zhang JJ; Xia Q
J Dig Dis; 2022 Nov; 23(11):642-650. PubMed ID: 36617995
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients.
Pereira MR; Scully BF; Pouch SM; Uhlemann AC; Goudie S; Emond JE; Verna EC
Liver Transpl; 2015 Dec; 21(12):1511-9. PubMed ID: 26136397
[TBL] [Abstract][Full Text] [Related]
9. Prediction models for carbapenem-resistant Enterobacterales carriage at liver transplantation: A multicenter retrospective study.
Freire MP; Rinaldi M; Terrabuio DRB; Furtado M; Pasquini Z; Bartoletti M; de Oliveira TA; Nunes NN; Lemos GT; Maccaro A; Siniscalchi A; Laici C; Cescon M; D Albuquerque LAC; Morelli MC; Song ATW; Abdala E; Viale P; Filho ADPC; Giannella M
Transpl Infect Dis; 2022 Dec; 24(6):e13920. PubMed ID: 35942941
[TBL] [Abstract][Full Text] [Related]
10. Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.
Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Abdel Fattah M; Haquin J; Macgowan A; Grier S; Gibbs J; Chazan B; Yanovskay A; Ben Ami R; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodriguez-Bano J; Morales I; Oliver A; Ruiz De Gopegui E; Cano A; Machuca I; Gozalo-Marguello M; Martinez Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
Clin Infect Dis; 2020 May; 70(11):2270-2280. PubMed ID: 31323088
[TBL] [Abstract][Full Text] [Related]
11. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
[TBL] [Abstract][Full Text] [Related]
12. [Risk Factors and Prognosis of Delirium After Liver Transplantation].
Ma Y; Peng WT; Liu J; Wan QQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):642-647. PubMed ID: 37248598
[TBL] [Abstract][Full Text] [Related]
13. Carbapenem-Resistant Enterobacteriaceae Acquired Before Liver Transplantation: Impact on Recipient Outcomes.
Freire MP; Oshiro IC; Pierrotti LC; Bonazzi PR; de Oliveira LM; Song AT; Camargo CH; van der Heijden IM; Rossi F; Costa SF; DʼAlbuquerque LA; Abdala E
Transplantation; 2017 Apr; 101(4):811-820. PubMed ID: 28009779
[TBL] [Abstract][Full Text] [Related]
14. Pre-transplant multidrug-resistant infections in liver transplant recipients-epidemiology and impact on transplantation outcome.
Lemos GT; Terrabuio DRB; Nunes NN; Song ATW; Oshiro ICV; D'Albuquerque LAC; Levin AS; Abdala E; Freire MP
Clin Transplant; 2024 Jan; 38(1):e15173. PubMed ID: 37877950
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
[TBL] [Abstract][Full Text] [Related]
16. Impact of a Multimodal Approach in Prevention of Surgical Site Infection in Hepatic Transplant Recipients.
Prieto J; Medina JC; López M; Rando K; Iglesias C; Harguindeguy M; Leites A; Etlin A; Menéndez J; Valverde M; Scalone P; Castelli J; Grecco G; Abelleira M; González LS; Gerona S
Transplant Proc; 2016 Mar; 48(2):658-64. PubMed ID: 27110024
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics of carbapenem-resistant
Sun Y; Zheng H; Zhang JL; Yu LX; Wang B; Gao W; Cai JZ; Liu YH
Zhonghua Er Ke Za Zhi; 2020 Aug; 58(8):640-645. PubMed ID: 32842384
[No Abstract] [Full Text] [Related]
18. Antibiotic prophylaxis with piperacillin-tazobactam reduces organ/space surgical site infection after pancreaticoduodenectomy: a retrospective and propensity score-matched analysis.
Yang Y; Sheng J; Cai Z; Zhu L; Lu C; Mao L; Qiu Y; Fu X
BMC Cancer; 2024 Feb; 24(1):251. PubMed ID: 38395787
[TBL] [Abstract][Full Text] [Related]
19. A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis.
Nguyen AD; Heil EL; Patel NK; Duffy A; Gilmore S
J Oncol Pharm Pract; 2016 Apr; 22(2):303-7. PubMed ID: 25567517
[TBL] [Abstract][Full Text] [Related]
20. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients.
Kalpoe JS; Sonnenberg E; Factor SH; del Rio Martin J; Schiano T; Patel G; Huprikar S
Liver Transpl; 2012 Apr; 18(4):468-74. PubMed ID: 22467548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
